Filana Therapeutics Stock (NASDAQ:FLNA)

Financials Chart

Previous Close

$1.45

52W Range

$1.39 - $4.98

50D Avg

$1.86

200D Avg

$2.46

Market Cap

$72.94M

Avg Vol (3M)

$544.32K

Beta

-0.68

Div Yield

-

FLNA Company Profile

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

20

IPO Date

Jul 14, 2000

Website

FLNA Performance

FLNA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-95.39M	$-141.45M	$-105.96M
Net Income	$-90.97M	$-24.34M	$-97.22M
EBITDA	$-94.45M	$-141.15M	$-105.80M
Basic EPS	$-1.88	$-0.53	$-2.32
Diluted EPS	$-1.88	$-1.46	$-2.32

Fiscal year ends in Dec 25 | Currency in USD